Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
85.92
-0.58 (-0.68%)
Feb 9, 2026, 9:32 AM EST - Market open
Ionis Pharmaceuticals Stock Forecast
Stock Price Forecast
The 22 analysts that cover Ionis Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $84.09, which forecasts a -2.12% decrease in the stock price over the next year. The lowest target is $39 and the highest is $110.
Price Target: $84.09 (-2.12%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ionis Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 9 | 9 | 9 | 9 | 9 |
| Buy | 6 | 8 | 8 | 9 | 9 | 9 |
| Hold | 4 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 21 | 21 | 22 | 22 | 22 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $77 → $87 | Buy | Maintains | $77 → $87 | +1.26% | Feb 6, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $82 → $100 | Buy | Maintains | $82 → $100 | +16.39% | Jan 5, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $82 → $95 | Buy | Maintains | $82 → $95 | +10.57% | Dec 17, 2025 |
| Leerink Partners | Leerink Partners | Buy Maintains $85 → $100 | Buy | Maintains | $85 → $100 | +16.39% | Dec 15, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $86 → $97 | Strong Buy | Maintains | $86 → $97 | +12.90% | Dec 9, 2025 |
Financial Forecast
Revenue This Year
915.23M
from 705.14M
Increased by 29.79%
Revenue Next Year
919.47M
from 915.23M
Increased by 0.46%
EPS This Year
-2.31
from -3.04
EPS Next Year
-3.13
from -2.31
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 968.8M | 1.2B | ||||
| Avg | 915.2M | 919.5M | ||||
| Low | 847.7M | 673.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 37.4% | 28.6% | ||||
| Avg | 29.8% | 0.5% | ||||
| Low | 20.2% | -26.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.87 | -1.59 | ||||
| Avg | -2.31 | -3.13 | ||||
| Low | -2.42 | -4.26 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.